Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This round of layoffs will affect 93 employees and will be effective on March 19, according to a Maryland Work Adjustment and Retraining Notification (WARN) filing.
The state’s WARN report also notes the CDMO’s dismissal of three other employees in nearby Baltimore.
In two waves of layoffs in the second half of last year, Catalent axed more than 400 jobs. Most of those reductions took place at the company’s manufacturing campus in Harmans, which includes two facilities that support phase 3 through commercial production of gene therapies…